Please ensure Javascript is enabled for purposes of website accessibility

Why Billionaire Leon Cooperman’s Large Stake in Chimera Investment Corporation Isn’t a Good Reason to Buy Its Stock

By John Maxfield - Jul 6, 2014 at 9:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Chimera Investment Corp. is a classic example of why you shouldn't follow in the footsteps of hedge funds and other institutional investors.

Despite a litany of problems at Chimera Investment Corp. (CIM 0.42%), the high-yielding mortgage REIT has nevertheless caught the eye of hedge-fund billionaire Leon Cooperman. In the last few years, the renowned investor has accumulated over 66 million shares in Chimera, equal to 6.44% of its outstanding share count.

Before calling your broker and following suit, however, I'd advise you to keep two things in mind. First, Chimera is a highly speculative stock that remains mired in an accounting debacle dating back to its inception as a publicly traded company. And second, Cooperman's resources give him an edge that simply isn't available to the average investor.

A primer on Chimera's "accounting error"
Because I've addressed Chimera's problems on multiple occasions in the past -- here's a good place to start -- I won't go into great detail here. In short, Chimera came clean in the middle of 2012 with the revelation that it had overstated its net income from 2008 through 2011 by a factor of three. Instead of earning a reported $1.06 billion, it had actually earned only $367 million.

Over the course of the next two years, Chimera missed nearly every filing deadline for its quarterly and annual financial statements, has been threatened with de-listing by the New York Stock Exchange, and suspiciously fired its former auditor Deloitte & Touche after the accounting giant informed Chimera that all of its financial statements since inception needed to be restated.

Chimera has nevertheless brushed off the accounting issue by saying it was an innocent mistake. According to a press release at the time, it had inadvertently used the wrong accounting rule to determine the treatment of other-than-temporary impairment on certain investments in non-agency residential mortgage-backed securities -- nevermind, of course, the size of the "accounting error" and the suspiciously convenient fact it was in Chimera's favor.

But innocent or not, what makes the accounting error inexcusable is who made it. More specifically, Chimera's chief financial officer at the time was a 30-something former "business consultant [from] Fort Lauderdale" with no evident qualifications for the position. How did she get it? She was the sister of the co-founder and now-CEO of Annaly Capital Management (NLY -0.44%), which established Chimera in 2007 and has managed it since then.

I trust you get the point. Say what you will about valuations and claims that Chimera has cleaned up its act, the fact remains that the management of this company -- and, for that matter, Annaly Capital Management -- leaves a lot to be desired. "You can't do good business with bad people," the late Walter Wriston used to say.

Why you shouldn't blindly follow Cooperman's lead
Given these facts, it may come as a surprise that someone with the reputation and track record of Cooperman would take such a large position in Chimera. Aside from being one of the wealthiest people in America, he's the founder and CEO of Omega Advisors, a New York-based hedge fund with more than $10 billion in assets under management. In a former life, moreover, Cooperman served as the chairman and CEO of Goldman Sachs Asset Management.

Although I can't speak on Cooperman's behalf, it seems safe to assume that his interest in Chimera stems from the fact that it's trading for a discount to book value -- I say this because he's a well-known value investor. When he first started accumulating the stock in 2012, in fact, it traded for as little as 70% of its stated book value. This means that a person with Cooperman's resources and expertise could theoretically generate a 30% return on investment simply by taking control of the company and liquidating its assets.

The point is that Cooperman's resources and expertise are an indispensable part of the equation. They give him access that an ordinary investor doesn't have. And they also mean that he can bend the ear of Chimera's wayward management. For instance, here's a selection from one of Chimera's recent regulatory filings:

Mr. Cooperman has engaged in communications with members of the Board of Directors of the Issuer regarding various matters related to the Issuer, including discussions regarding the Issuer's operations, business, strategies and strategic direction. These discussions have reviewed, and may continue to review, options for enhancing shareholder value through various strategic alternatives, improving the Issuer's operational and financial execution, and general corporate matters.

When was the last time you "engaged in communications" with a company's board members about "various strategic alternatives" and improving "operational and financial execution"? My guess is never. And this is the point. You see, Cooperman could very well have other objectives that conflict with the average Chimera stakeholder. It isn't his job to protect or advise them. If anything, he's an adversary that's justifiably bent on maximizing his take to the exclusion of others.

To this end, consider this anecdote from my colleague Morgan Housel about the "worst investment" he ever made:

The housing market was crumbling, and a smart value investor I idolized began purchasing shares in a small, battered specialty lender. I didn't know anything about the company, but I followed him anyway, buying shares myself. It became my largest holding -- which was unfortunate when the company went bankrupt less than a year later.

Only later did I learn the full story. As part of his investment, the guru I followed also controlled a large portion of the company's debt and preferred stock, purchased at special terms that effectively gave him control over its assets when it went out of business. The company's stock also made up one-fifth the weighting in his portfolio as it did in mine. I lost everything. He made a decent investment.

The Foolish takeaway
Just to be clear, I'm not saying that Chimera is on the verge of bankruptcy -- though it wouldn't surprise me if that eventually happened. What I am saying, however, is that no one other than Cooperman and perhaps those in his inner circle knows why he's established such a large position in the ailing mortgage REIT. Nor do we know, to Housel's point, what Cooperman's strategy is for maximizing his return on investment. Perhaps it's in line with other holders of common stock. But perhaps it isn't.

The takeaway is that Cooperman's position in Chimera -- or, for that matter, any institutional investor's stake in any company -- should at best be considered irrelevant when drawing your own conclusion about a stock. And at worst it should be viewed skeptically. It pays to remember that the only person looking out for your interests is you. Forgetting this lesson is a great way to pad someone else's pocket.

John Maxfield has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Annaly Capital Management, Inc. Stock Quote
Annaly Capital Management, Inc.
$6.79 (-0.44%) $0.03
Chimera Investment Corporation Stock Quote
Chimera Investment Corporation
$9.65 (0.42%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.